ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VAL Valirx Plc

0.80
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 0.80 0.80 0.80 735,082 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 9k -2.04M -0.0154 -0.52 1.06M

ValiRx PLC Investor Evening

09/09/2024 7:00am

RNS Regulatory News


RNS Number : 2642D
ValiRx PLC
09 September 2024
 

ValiRx plc

("ValiRx" or the "Company")

Investor Evening - Tuesday 24 September 2024

London, UK - ValiRx Plc is pleased to welcome current shareholders and interested investors to a ValiRx Plc Investor Evening organised by Shard Capital Partners LLP on Tuesday, 24 September 2024.

At the event, a presentation will be delivered by Dr Mark Eccleston, Chief Executive of the Company, followed by a Q&A session. Drinks will be provided.

The event will take place at 25 Eccleston Place London SW1W 9NF, London and will start at 5.30pm (UK).

To gain admission, please RSVP by completing the attendance form via the following link: https://corporate-update-from-fusion-antibodies-plc-and-valirx-plc-tick.eventbrite.co.uk

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

ValiRx plc

Dr Mark Eccleston, CEO

Tel: +44 (0) 115 784 0026

www.valirx.com

info@valirx.com

V Formation (Public Relations)

Lucy Wharton - Senior PR Executive

Sue Carr - Director

 

+44 (0) 115 787 0206

www.vformation.biz

lucy@vformation.biz

sue@vformation.biz

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray/Jo Turner/Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Shard Capital Partners LLP (Sole Broker)

Damon Heath

Tel: +44 (0) 20 7186 9000

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBGGDCRBGDGSL

1 Year Valirx Chart

1 Year Valirx Chart

1 Month Valirx Chart

1 Month Valirx Chart

Your Recent History

Delayed Upgrade Clock